Tags

Type your tag names separated by a space and hit enter

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
J Neuroinflammation 2016; 13(1):281JN

Abstract

BACKGROUND

Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) are present in a subset of aquaporin-4 (AQP4)-IgG-negative patients with optic neuritis (ON) and/or myelitis. Little is known so far about brainstem involvement in MOG-IgG-positive patients.

OBJECTIVE

To investigate the frequency, clinical and paraclinical features, course, outcome, and prognostic implications of brainstem involvement in MOG-IgG-positive ON and/or myelitis.

METHODS

Retrospective case study.

RESULTS

Among 50 patients with MOG-IgG-positive ON and/or myelitis, 15 (30 %) with a history of brainstem encephalitis were identified. All were negative for AQP4-IgG. Symptoms included respiratory insufficiency, intractable nausea and vomiting (INV), dysarthria, dysphagia, impaired cough reflex, oculomotor nerve palsy and diplopia, nystagmus, internuclear ophthalmoplegia (INO), facial nerve paresis, trigeminal hypesthesia/dysesthesia, vertigo, hearing loss, balance difficulties, and gait and limb ataxia; brainstem involvement was asymptomatic in three cases. Brainstem inflammation was already present at or very shortly after disease onset in 7/15 (47 %) patients. 16/21 (76.2 %) brainstem attacks were accompanied by acute myelitis and/or ON. Lesions were located in the pons (11/13), medulla oblongata (8/14), mesencephalon (cerebral peduncles; 2/14), and cerebellar peduncles (5/14), were adjacent to the fourth ventricle in 2/12, and periaqueductal in 1/12; some had concomitant diencephalic (2/13) or cerebellar lesions (1/14). MRI or laboratory signs of blood-brain barrier damage were present in 5/12. Cerebrospinal fluid pleocytosis was found in 11/14 cases, with neutrophils in 7/11 (3-34 % of all CSF white blood cells), and oligoclonal bands in 4/14. Attacks were preceded by acute infection or vaccination in 5/15 (33.3 %). A history of teratoma was noted in one case. The disease followed a relapsing course in 13/15 (87 %); the brainstem was involved more than once in 6. Immunosuppression was not always effective in preventing relapses. Interferon-beta was followed by new attacks in two patients. While one patient died from central hypoventilation, partial or complete recovery was achieved in the remainder following treatment with high-dose steroids and/or plasma exchange. Brainstem involvement was associated with a more aggressive general disease course (higher relapse rate, more myelitis attacks, more frequently supratentorial brain lesions, worse EDSS at last follow-up).

CONCLUSIONS

Brainstem involvement is present in around one third of MOG-IgG-positive patients with ON and/or myelitis. Clinical manifestations are diverse and may include symptoms typically seen in AQP4-IgG-positive neuromyelitis optica, such as INV and respiratory insufficiency, or in multiple sclerosis, such as INO. As MOG-IgG-positive brainstem encephalitis may take a serious or even fatal course, particular attention should be paid to signs or symptoms of additional brainstem involvement in patients presenting with MOG-IgG-positive ON and/or myelitis.

Authors+Show Affiliations

Molecular Neuroimmunology Group, Department of Neurology, University Hospital Heidelberg, Otto Meyerhof Center, Im Neuenheimer Feld 350, 69120, Heidelberg, Germany. sven.jarius@med.uni-heidelberg.de.Department of Neurology, Ruhr University Bochum, Bochum, Germany.Department of Neurology, Charité - University Medicine Berlin, Berlin, Germany.Department of Neurology and Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.Department of Neurology, Ruhr University Bochum, Bochum, Germany.Department of Neurology, NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Charité University Medicine, Berlin, Germany. Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany.Department of Neurology, Hannover Medical School, Hannover, Germany.Department of Neurology, Hannover Medical School, Hannover, Germany.Department of Neurology, NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Charité University Medicine, Berlin, Germany. Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany.Department of Neurology, University of Rostock, Rostock, Germany.Department of Neurology, Albert Ludwigs University, Freiburg, Germany.Department of Neurology, Heinrich Heine University, Düsseldorf, Germany.Department of Neurology, Albert Ludwigs University, Freiburg, Germany.Department of Neurology, Heinrich Heine University, Düsseldorf, Germany.Molecular Neuroimmunology Group, Department of Neurology, University Hospital Heidelberg, Otto Meyerhof Center, Im Neuenheimer Feld 350, 69120, Heidelberg, Germany.Molecular Neuroimmunology Group, Department of Neurology, University Hospital Heidelberg, Otto Meyerhof Center, Im Neuenheimer Feld 350, 69120, Heidelberg, Germany.Department of Neuroradiology, Ruhr University Bochum, Bochum, Germany.Molecular Neuroimmunology Group, Department of Neurology, University Hospital Heidelberg, Otto Meyerhof Center, Im Neuenheimer Feld 350, 69120, Heidelberg, Germany.Institute of Experimental Immunology, affiliated to Euroimmun AG, Lübeck, Germany.Department of Neurology, Julius Maximilians University, Würzburg, Germany.Department of Neurology, NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Charité University Medicine, Berlin, Germany. Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany.Department of Neurology, Charité - University Medicine Berlin, Berlin, Germany.Department of Neurology, Charité - University Medicine Berlin, Berlin, Germany.IRCCS, C. Mondino National Neurological Institute, Pavia, Italy.Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.Department of Neurology, NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Charité University Medicine, Berlin, Germany. Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany.Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.Molecular Neuroimmunology Group, Department of Neurology, University Hospital Heidelberg, Otto Meyerhof Center, Im Neuenheimer Feld 350, 69120, Heidelberg, Germany.No affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27802825

Citation

Jarius, Sven, et al. "MOG-IgG in NMO and Related Disorders: a Multicenter Study of 50 Patients. Part 3: Brainstem Involvement - Frequency, Presentation and Outcome." Journal of Neuroinflammation, vol. 13, no. 1, 2016, p. 281.
Jarius S, Kleiter I, Ruprecht K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation. 2016;13(1):281.
Jarius, S., Kleiter, I., Ruprecht, K., Asgari, N., Pitarokoili, K., Borisow, N., ... Wildemann, B. (2016). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. Journal of Neuroinflammation, 13(1), p. 281.
Jarius S, et al. MOG-IgG in NMO and Related Disorders: a Multicenter Study of 50 Patients. Part 3: Brainstem Involvement - Frequency, Presentation and Outcome. J Neuroinflammation. 2016 11 1;13(1):281. PubMed PMID: 27802825.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. AU - Jarius,Sven, AU - Kleiter,Ingo, AU - Ruprecht,Klemens, AU - Asgari,Nasrin, AU - Pitarokoili,Kalliopi, AU - Borisow,Nadja, AU - Hümmert,Martin W, AU - Trebst,Corinna, AU - Pache,Florence, AU - Winkelmann,Alexander, AU - Beume,Lena-Alexandra, AU - Ringelstein,Marius, AU - Stich,Oliver, AU - Aktas,Orhan, AU - Korporal-Kuhnke,Mirjam, AU - Schwarz,Alexander, AU - Lukas,Carsten, AU - Haas,Jürgen, AU - Fechner,Kai, AU - Buttmann,Mathias, AU - Bellmann-Strobl,Judith, AU - Zimmermann,Hanna, AU - Brandt,Alexander U, AU - Franciotta,Diego, AU - Schanda,Kathrin, AU - Paul,Friedemann, AU - Reindl,Markus, AU - Wildemann,Brigitte, AU - ,, Y1 - 2016/11/01/ PY - 2016/04/01/received PY - 2016/09/09/accepted PY - 2016/11/3/pubmed PY - 2017/10/7/medline PY - 2016/11/3/entrez KW - Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG) KW - Ataxia KW - Brainstem encephalitis KW - Cerebellitis KW - Diplopia Internuclear ophthalmoplegia (INO) KW - Facial nerve palsy KW - Hearing loss KW - Intractable nausea and vomiting KW - Longitudinally extensive transverse myelitis (LETM) KW - MOG-IgG KW - Myelin oligodendrocyte glycoprotein (MOG) antibodies KW - Myelitis KW - Neuromyelitis optica spectrum disorders (NMOSD) KW - Optic neuritis KW - Respiratory insufficiency KW - Rhombencephalitis SP - 281 EP - 281 JF - Journal of neuroinflammation JO - J Neuroinflammation VL - 13 IS - 1 N2 - BACKGROUND: Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) are present in a subset of aquaporin-4 (AQP4)-IgG-negative patients with optic neuritis (ON) and/or myelitis. Little is known so far about brainstem involvement in MOG-IgG-positive patients. OBJECTIVE: To investigate the frequency, clinical and paraclinical features, course, outcome, and prognostic implications of brainstem involvement in MOG-IgG-positive ON and/or myelitis. METHODS: Retrospective case study. RESULTS: Among 50 patients with MOG-IgG-positive ON and/or myelitis, 15 (30 %) with a history of brainstem encephalitis were identified. All were negative for AQP4-IgG. Symptoms included respiratory insufficiency, intractable nausea and vomiting (INV), dysarthria, dysphagia, impaired cough reflex, oculomotor nerve palsy and diplopia, nystagmus, internuclear ophthalmoplegia (INO), facial nerve paresis, trigeminal hypesthesia/dysesthesia, vertigo, hearing loss, balance difficulties, and gait and limb ataxia; brainstem involvement was asymptomatic in three cases. Brainstem inflammation was already present at or very shortly after disease onset in 7/15 (47 %) patients. 16/21 (76.2 %) brainstem attacks were accompanied by acute myelitis and/or ON. Lesions were located in the pons (11/13), medulla oblongata (8/14), mesencephalon (cerebral peduncles; 2/14), and cerebellar peduncles (5/14), were adjacent to the fourth ventricle in 2/12, and periaqueductal in 1/12; some had concomitant diencephalic (2/13) or cerebellar lesions (1/14). MRI or laboratory signs of blood-brain barrier damage were present in 5/12. Cerebrospinal fluid pleocytosis was found in 11/14 cases, with neutrophils in 7/11 (3-34 % of all CSF white blood cells), and oligoclonal bands in 4/14. Attacks were preceded by acute infection or vaccination in 5/15 (33.3 %). A history of teratoma was noted in one case. The disease followed a relapsing course in 13/15 (87 %); the brainstem was involved more than once in 6. Immunosuppression was not always effective in preventing relapses. Interferon-beta was followed by new attacks in two patients. While one patient died from central hypoventilation, partial or complete recovery was achieved in the remainder following treatment with high-dose steroids and/or plasma exchange. Brainstem involvement was associated with a more aggressive general disease course (higher relapse rate, more myelitis attacks, more frequently supratentorial brain lesions, worse EDSS at last follow-up). CONCLUSIONS: Brainstem involvement is present in around one third of MOG-IgG-positive patients with ON and/or myelitis. Clinical manifestations are diverse and may include symptoms typically seen in AQP4-IgG-positive neuromyelitis optica, such as INV and respiratory insufficiency, or in multiple sclerosis, such as INO. As MOG-IgG-positive brainstem encephalitis may take a serious or even fatal course, particular attention should be paid to signs or symptoms of additional brainstem involvement in patients presenting with MOG-IgG-positive ON and/or myelitis. SN - 1742-2094 UR - https://www.unboundmedicine.com/medline/citation/27802825/MOG_IgG_in_NMO_and_related_disorders:_a_multicenter_study_of_50_patients__Part_3:_Brainstem_involvement___frequency_presentation_and_outcome_ L2 - https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0719-z DB - PRIME DP - Unbound Medicine ER -